证券代码：301093 证券简称：华兰股份 公告编号：2026-007 江苏华兰药用新材料股份有限公司 关于向全资子公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 本次增资概述 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）于 2026 年 1 月 21 日召开第六届董事会第十二次会议，审议通过了《关于向全资子 公司增资的议案》。 海南灵擎数智医药科技有限公司（以下简称"灵擎数智"）为公司全资子公 司，系公司在 AI 医药领域的重要业务布局平台，主要聚焦于人工智能创新药研 发解决方案及服务，助力人工智能技术在药物研发及产业应用等方向的研发与 商业化推进。鉴于 AI 医药行业技术迭代快、研发投入强度高、对资本实力和资 源整合能力要求较高，为进一步增强全资子公司的资本实力，夯实其未来研发 和业务拓展基础，提升其链接产业优质资源的能力，推动其与全球上下游企业、 技术团队、科研机构建立深度合作，加快公司整体战略发展目标的实现，董事 会同意公司以自有资金人民币 45,000 万元对全资子公司灵擎数智进行增资。本 次增资完成后，灵擎 ...

第六届董事会第十二次会议决议公告 证券代码：301093 证券简称：华兰股份 公告编号：2026-006 江苏华兰药用新材料股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）第 六届董事会第十二次会议通知于 2026 年 1 月 15 日以邮件、电话等方式向各位 董事发出，会议于 2026 年 1 月 21 日以现场会议结合通讯形式召开。本次会议 由公司董事长华一敏先生召集并主持，应出席会议的董事 9 人，实际出席会议 的董事 9 人，其中华一敏先生、华国平先生、肖锋先生、崔珂女士、姚茗芳女 士、单体超先生、陈岗先生、刘力先生、侯绪超先生以通讯表决方式出席本次 董事会会议，公司高级管理人员列席了会议。本次会议的召集、召开及表决符 合《公司法》等有关法律、法规、规范性文件和《公司章程》的规定，会议合 法、有效。 二、 董事会会议审议情况 1、会议以 7 票同意、0 票反对、2 票弃权，审议通过了《关于向全资子公 司增资的议案》。 本议案已经战略与投资委员会 20 ...

Investment Rating - The report maintains a "Neutral" rating for the pharmaceutical and biotechnology industry [7][49]. Core Insights - The pharmaceutical sector has experienced a decline of 0.68% recently, ranking 19th among 31 primary sub-industries. The chemical pharmaceuticals, biological products, medical devices, pharmaceutical commerce, traditional Chinese medicine, and medical services have shown varying performance, with the medical services sector increasing by 3.29% [12][26]. - The collaboration between NVIDIA and Eli Lilly to establish an AI joint innovation lab aims to address long-standing challenges in the pharmaceutical industry, with a projected investment of up to $1 billion over five years [13]. - Tempus AI reported a revenue of approximately $1.27 billion for 2025, marking an 83% year-on-year increase, driven by significant growth in diagnostic services [14]. Summary by Sections Recent Performance - The pharmaceutical sector's return since the beginning of 2026 is 7.08%, outperforming the CSI 300 index, which returned 2.20%. However, the pharmaceutical sector lagged behind the CSI 300 by 4.88 percentage points [26]. Market Dynamics - The pharmaceutical sector's valuation is currently at 34.5 times PE based on 2026 earnings forecasts, representing a 35% premium over the overall A-share market (excluding financials). The TTM valuation stands at 30.4 times PE, below the historical average of 35.0 times PE [29]. Individual Stock Performance - Notable stock performances include Baolait and Hualan Biological, which saw increases of 48.76% and 32.72%, respectively, while stocks like Xiangrikui and Luyuan Pharmaceutical experienced declines of 37.48% and 26.62% [35]. Key Companies to Watch - The report highlights companies such as Sanofi, Innovent Biologics, and others as key focuses for potential investment opportunities [40].

Core Viewpoint - Hualan Biological Engineering has intensified its strategy in AI-driven pharmaceuticals by expanding its AI Medical Expert Committee and electing new members, indicating a commitment to leveraging AI in drug development [1][2] Group 1: Company Developments - Hualan Biological announced the addition of Hu Tony Ye to its AI Medical Expert Committee, enhancing the committee's expertise with his extensive background in biomedical engineering and industry connections [2] - The company plans to invest 20 million yuan in Suzhou Kema Biotechnology, which is expected to benefit from the technological integration of its shareholders and Hualan's extensive client network [1][2] Group 2: Market Outlook - Huatai Securities forecasts a significant growth in the global AI-enabled drug development market, projecting an increase from $11.9 billion in 2023 to $74.6 billion by 2032, with a compound annual growth rate of 22.6% [3] - The report highlights that Hualan's core business is expected to maintain growth, particularly in its cartridge business, with revenue growth projected between 5% and 15% [3] Group 3: Financial Projections - Huatai Securities has raised its target price for Hualan from 39.46 yuan to 69.60 yuan, maintaining a "buy" rating based on the company's growth potential in AI pharmaceuticals and ongoing order fulfillment [4]

Group 1 - The A-share market experienced a downturn on January 20, with the medical device ETF (562600) declining by 1.52% in the afternoon session. Notably, Hualan Biological Engineering rose by 4.65%, and Haitai New Light increased by 1% [1] - Baichuan Intelligent recently launched its new medical AI model, Baichuan-M3, which outperformed OpenAI's latest flagship model GPT-5.2 in clinical consultation, hallucination suppression, and HealthBench evaluations, marking a significant advancement in medical AI [1] - CITIC Securities anticipates that the reliability of medical AI models in clinical decision-making will accelerate the commercialization of AI in hierarchical diagnosis and auxiliary diagnosis, benefiting companies with strong medical data accumulation and model optimization capabilities [1] Group 2 - The medical device industry is experiencing robust growth, and investors can leverage the medical device ETF (562600) to capture growth opportunities. This ETF tracks the CSI All-Share Medical Device Index, with a 23.8% allocation to brain-computer interface stocks, the highest among similar ETFs [2] - The medical device sector constitutes 89.2% of the ETF's holdings, indicating a concentrated focus that effectively captures growth opportunities in niche segments. Investors can also consider the 华夏中证全指医疗器械ETF发起式联接A (021250) and 华夏中证全指医疗器械ETF发起式联接C (021251) for convenient investment [2]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The pharmaceutical and biotechnology index decreased by 0.68% this week, underperforming the CSI 300 index by 0.11 percentage points, ranking 19th in industry performance [12] - The healthcare sector has shown significant growth, with the medical services sub-sector increasing by 16.04% year-to-date, while traditional Chinese medicine has the lowest growth at 1.86% [17][19] - The J.P. Morgan Health Conference highlighted the strategic advancements of top global pharmaceutical companies, with over 20 Chinese firms participating, indicating a trend towards overseas collaboration in innovative drugs [34] Summary by Sections Market Review - The pharmaceutical index has risen by 7.08% from the beginning of 2026 to January 16, outperforming the CSI 300 index by 4.88 percentage points, ranking 8th in industry performance [12] - The medical services sub-sector has the highest year-to-date growth at 16.04%, while the lowest is traditional Chinese medicine at 1.86% [19] Individual Stock Performance - In the A-share market, 206 out of 478 pharmaceutical stocks rose, with the top five performers being Baolait (up 48.76%), Hualan Biological (up 32.72%), and Tianzhihang (up 27.67%) [23] - In the Hong Kong market, 59 out of 116 pharmaceutical stocks increased, with Ark Health leading at 51.66% growth [26] Industry News and Policies - The sixth batch of national high-value medical consumables procurement was opened on January 13, with 202 companies winning bids for 440 products [29] - Medtronic announced a strategic partnership with Precision Neuroscience to develop integrated solutions combining their technologies [29] - Boston Scientific plans to acquire Penumbra for approximately $14.5 billion, enhancing its portfolio in peripheral vascular interventions [30] Weekly Insights - The medical services sector's strong performance is attributed to positive revenue growth, with medical commercial and services sectors showing year-on-year revenue increases of 0.56% and 3.99%, respectively [33] - The J.P. Morgan Health Conference served as a significant platform for discussing trends in drug development and investment strategies, with a focus on AI and international collaborations [34]

江苏华兰药用新材料股份有限公司 AI 医药专家委员会工作细则 第一章 总则 （一）对公司的发展战略进行研究并提出建议； （二）对公司中长期发展规划进行研究并提出建议； 第一条 为适应公司战略发展需要，建立健全公司投资决策程序，完善公司治理 结构，增强公司决策科学性和核心竞争力，根据《中华人民共和国公司法》（以 下简称"《公司法》"）《上市公司治理准则》《江苏华兰药用新材料股份有限公司 章程》（以下简称"《公司章程》"）及其他有关规定，公司设立 AI 医药专家委员 会，并制定本细则。 第二条 AI 医药专家委员会是一个为董事会战略与投资委员会提供决策意见与 建议的机构，对董事会战略与投资委员会负责；其主要职责是对公司发展战略、 中长期规划、重大投融资以及产业并购决策以及重大项目实施情况进行研究并提 出意见和建议。 第二章 AI 医药专家委员会组成 第三条 AI 医药专家委员会由 4 名委员组成。AI 医药专家委员会委员应熟悉国 家相关法律、法规和有关规定；在相关技术领域或公司经营管理方面具有较高权 威和影响力；独立工作能力和综合分析能力强，对涉及公司发展战略、重大投资 方面的问题具有较好的判断能力。 第四条 A ...

一、 董事会会议召开情况 江苏华兰药用新材料股份有限公司（以下简称"华兰股份"或"公司"）第 六届董事会第十一次会议通知于 2026 年 1 月 13 日以邮件、电话等方式向各位 董事发出，会议于 2026 年 1 月 19 日以现场会议结合通讯形式召开。本次会议 由公司董事长华一敏先生召集并主持，应出席会议的董事 9 人，实际出席会议 的董事 9 人，其中华国平先生、肖锋先生、崔珂女士、姚茗芳女士、单体超先 生、陈岗先生、刘力先生、侯绪超先生以通讯表决方式出席本次董事会会议， 公司高级管理人员列席了会议。本次会议的召集、召开及表决符合《公司法》 等有关法律、法规、规范性文件和《公司章程》的规定，会议合法、有效。 二、 董事会会议审议情况 1、会议以 9 票同意、0 票反对、0 票弃权，审议通过了《关于增加公司 AI 医药专家委员会委员人数暨修订的议案》。 为进一步完善公司治理结构，提高公司 AI 医药专家委员会决策的科学性、 有效性，更快推动公司 AI 医药业务发展、链接产业优质资源，更好地适配公司 经营发展需要，董事会同意 AI 医药专家委员会委员人数由 3 名增加至 4 名（其 中主任委员 1 名，委员 ...

从资金流向上来看，当日医疗器械板块主力资金净流出6.07亿元，游资资金净流入5.15亿元，散户资金净 流入9141.19万元。医疗器械板块个股资金流向见下表： 证券之星消息，1月19日医疗器械板块较上一交易日下跌0.42%，华康洁净领跌。当日上证指数报收于 4114.0，上涨0.29%。深证成指报收于14294.05，上涨0.09%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301093 | 华兰股份 | 68.80 | 7.84% | 11.86万 | | 8.07亿 | | 300314 | 載维医疗 | 14.89 | 6.51% | 10.05万 | | 1.45亿 | | 301097 | 天益医疗 | 55.55 | 3.50% | ● 1.56万 | 8499.31万 | | | 301290 | 东星医疗 | 29.04 | 3.16% | - 3.38万 | 9801.24万 | | | 300246 | 宝菜特 | 14.2 ...

Group 1 - The A-share market experienced fluctuations on January 19, with the medical device ETF (562600) declining by 0.54% in the afternoon session [1] - Notable stock performances included Hualan Biological Engineering rising by 7.29%, Yirui Technology by 2.34%, Dian Diagnostics by 1.94%, and Aidi Te by 1.82% [1] - The medical device ETF (562600) has seen significant capital inflow, with a net inflow of 125 million yuan over the past five days and 256 million yuan over the past ten days [1] Group 2 - The medical device sector is expected to benefit from opportunities in overseas expansion, brain-computer interfaces, and AI healthcare by 2026 [2] - The overseas business revenue of the second-largest weight stock in the medical device ETF, United Imaging Healthcare, grew by 41.97% year-on-year in the first three quarters of 2025, becoming a significant source of revenue for the company [1][2] - The brain-computer interface market is at a critical turning point, with demand expected to be released, supported by China's 14th Five-Year Plan [2] - AI applications in healthcare are gradually being implemented, with Ant Group's AI health manager AQ reaching over 30 million monthly active users by January 2026 [2] - The medical device ETF (562600) tracks the CSI All-Share Medical Device Index, with a 23.8% allocation to brain-computer interfaces, the highest among similar ETFs, effectively capturing growth opportunities in niche markets [2]